XTL Biopharmaceuticals Ltd ADR (XTLB NASDAQ) stock market data APIs
$1.2062
0(0%)
as of May 30, 2025
Try our APIs with
free plan!
XTL Biopharmaceuticals Ltd ADR Financial Data Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Prev. Close
1.2062
Open
1.2062
High
1.2506
Low
1.1098
52 wk Range
0.92-3.05
Market Cap
10 577 K
Shares Outstanding
8 814 K
Revenue
451 K
EPS
-0.0289
Beta
1.038
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get XTL Biopharmaceuticals Ltd ADR data using free add-ons & libraries
Get XTL Biopharmaceuticals Ltd ADR Fundamental Data
XTL Biopharmaceuticals Ltd ADR Fundamental data includes:
- Net Revenue: 451 K
- EBITDA: -1 973 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
XTL Biopharmaceuticals Ltd ADR News
New
XTL Names Mr. Noam Band as its New Chief Executive Officer
Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL...
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets...
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets...
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual Meeting
Former CEO/Director Dr. Morris C. Laster Believes Immediate Change is Required to Scopus's Board to Ensure Effective, Independent Oversight of Company's Affairs Deeply Concerned about Allegations of ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
